MEDICAL ONCOLOGY · LIV VADISTANBUL
Doç. Dr. Murat Ayhan
Medical oncologist · Liv Hospital Vadistanbul
Murat Ayhan is a medical oncologist. He graduated from Dicle University Faculty of Medicine in 2007 and completed internal medicine training at Istanbul Medeniyet University Göztepe Training and Research Hospital in 2014, followed by medical oncology training at Kartal Dr. Lütfi Kırdar City Hospital, completed in 2021. He received the associate professor title in 2023 and practises at Liv Hospital. He has also worked at Adıyaman University Training and Research Hospital and at Ümraniye Training and Research Hospital. His clinical work covers breast, lung, colorectal, gynaecological and genitourinary cancers, together with molecular oncology and targeted and immune therapies. His recent publications address frontline enfortumab vedotin with pembrolizumab in metastatic urothelial carcinoma and prognostic biomarker expression in advanced hepatocellular carcinoma. He is a member of the European Society for Medical Oncology and the Turkish Society of Medical Oncology.
Specialties:
Oncology
46
indexed works (OpenAlex)
6
h-index (OpenAlex)
Breast cancerLung cancerColorectal cancerGenitourinary cancersGynaecological cancersTargeted therapy and immunotherapy
A BergemHealth coordinator arranges contact with the professor within 24–48 hours on business days.
Direct contract with BergemHealth
CONSULTATION LANGUAGES
Turkish
ISTANBUL · 08/2026
EDUCATION & CAREER
Timeline
2007
Medical degree, Dicle University Faculty of Medicine
2014
Internal medicine specialty, Istanbul Medeniyet University Göztepe Training and Research Hospital
2021
Medical oncology training completed, Kartal Dr. Lütfi Kırdar City Hospital
2023
Associate professor title
current
Medical Oncology, Liv Hospital Vadistanbul (also listed at Liv Hospital Ulus)
PUBLICATIONS
Scientific work
-
2026Clinical Genitourinary Cancer«Real-World Efficacy and Safety of Frontline Enfortumab Vedotin Plus Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Study and Review of the Literature»
-
2026Journal of International Medical Research«Expression and prognostic importance of lymphocyte activation gene 3 and CD73 in advanced or metastatic hepatocellular carcinoma»
CLINIC
Where they practise
Direct contract with BergemHealth at every listed clinic.
REQUEST
Tell me about your case — I’ll read it personally.
Fill in the short form on the consultation page — diagnosis, preferred timing, attached records. We assemble a tumour board for your case and reply within 4 hours.
Open the consultation form- Reply within 4 hours during business hours
- Confidentiality guaranteed
- Coordinator-translator inside the doctor’s office
- Tumour board of 2–3 professors within 72 hours
OTHER DOCTORS
Similar BergemHealth professors
Adjacent specialties and second opinions. Direct contracts, verified cases.